VYNE Therapeutics Appoints New CEO, Files 8-K

TL;DR

VYNE names Edick CEO, files 8-K. New leadership incoming.

AI Summary

VYNE Therapeutics Inc. announced on December 12, 2024, the appointment of Dr. Paul R. Edick as Chief Executive Officer and a member of the Board of Directors. Dr. Edick, who previously served as interim CEO, brings extensive experience in the pharmaceutical industry. The company also reported on matters submitted to a vote of security holders and filed financial statements and exhibits.

Why It Matters

The appointment of a new CEO can signal a strategic shift or renewed focus for the company, potentially impacting its future direction and stock performance.

Risk Assessment

Risk Level: medium — Leadership changes and routine filings can introduce uncertainty, but the specific impact depends on the company's performance and strategic execution.

Key Players & Entities

• VYNE Therapeutics Inc. (company) — Registrant
• Dr. Paul R. Edick (person) — Appointed CEO and Board Member
• December 12, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar

Filing Documents

• tm2430841d1_8k.htm (8-K) — 42KB
• tm2430841d1_ex10-1.htm (EX-10.1) — 14KB
• 0001104659-24-127997.txt ( ) — 232KB
• vyne-20241212.xsd (EX-101.SCH) — 3KB
• vyne-20241212_lab.xml (EX-101.LAB) — 33KB
• vyne-20241212_pre.xml (EX-101.PRE) — 22KB
• tm2430841d1_8k_htm.xml (XML) — 4KB

02 Departure of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . (e) Compensatory Arrangements of Certain Officers Approval of the 2023 Equity Incentive Plan Amendment On December 12, 2024, at the 2024 annual meeting of stockholders (the " Annual Meeting ") of VYNE Therapeutics Inc. (the " Company "), the stockholders of the Company approved an amendment (the " Amendment ") to the Company's 2023 Equity Incentive Plan (the " 2023 Plan ") to (i) increase the number of shares available for issuance under the 2023 Plan by 1,520,000 shares, (ii) eliminate "liberal" share recycling with respect to awards of share options and share appreciation rights, and (iii) increase the limit on shares that may be issued pursuant to the exercise of incentive share options under the 2023 Plan by 1,520,000 shares. Upon the recommendation of the Compensation Committee of the Company's Board of Directors (the " Board "), the Board approved the Amendment on November 6, 2024, subject to stockholder approval. The Amendment became effective immediately upon stockholder approval at the Annual Meeting. For more information about the Amendment, see the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 12, 2024 (the " Proxy Statement "), the relevant portions of which are incorporated herein by reference. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed as Exhibit 10.1 to this report and is incorporated by reference herein.

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On December 12, 2024, the Company held its Annual Meeting. The stockholders considered five proposals, each of which is described in more detail in the Proxy Statement. Of the 14,751,433 shares outstanding as of the record date, 11,014,460 shares, or 74.7%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. Proposal No. 1 : The election of two nominees to serve as Class III directors to hold office until the 2027 annual meeting of stockholders and until their respective successors are elected. The votes were cast as follows: Name Votes For Votes Withheld David Domzalski 8,473,554 37,335 Patrick LePore 7,636,731 874,158 Broker Non-Votes: 2,503,571 All nominees were elected. Proposal No. 2 : Ratification of the selection by the audit committee of the board of directors of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: Votes For Votes Against Abstentions Ratification of appointment of Baker Tilly US, LLP 10,977,445 18,210 18,805 Proposal No. 3 : Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. The Company's stockholders approved the compensation of the Company's named executive officers. The votes were cast as follows: Votes For Votes Against Abstentions Broker Non-Votes Advisory approval of named executive officer compensation 6,694,462 1,801,287 15,140 2,503,571 Proposal No. 4 : Indication, on an advisory basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstentions Advisory indication of preferred frequency of future share

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 10.1 First Amendment to the VYNE Therapeutics Inc. 2023 Equity Incentive Plan 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYNE THERAPEUTICS INC . Date: December 12, 2024 /s/ Mutya Harsch Mutya Harsch Chief Legal Officer and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR